Literature DB >> 20686503

AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3.

M Wunderlich, F-S Chou, K A Link, B Mizukawa, R L Perry, M Carroll, J C Mulloy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20686503      PMCID： PMC5439963          DOI： 10.1038/leu.2010.158

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

Review 1.  Humanized mice in translational biomedical research.

Authors:  Leonard D Shultz; Fumihiko Ishikawa; Dale L Greiner
Journal:  Nat Rev Immunol       Date:  2007-02       Impact factor: 53.106

2.  Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element.

Authors:  James C Mulloy; Jorg Cammenga; Francisco J Berguido; Kaida Wu; Ping Zhou; Raymond L Comenzo; Suresh Jhanwar; Malcolm A S Moore; Stephen D Nimer
Journal:  Blood       Date:  2003-08-28       Impact factor: 22.113

3.  The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells.

Authors:  James C Mulloy; Jörg Cammenga; Karen L MacKenzie; Francisco J Berguido; Malcolm A S Moore; Stephen D Nimer
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

4.  Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors.

Authors:  M Feuring-Buske; B Gerhard; J Cashman; R K Humphries; C J Eaves; D E Hogge
Journal:  Leukemia       Date:  2003-04       Impact factor: 11.528

5.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

6.  Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability.

Authors:  Mark Wunderlich; Ondrej Krejci; Junping Wei; James C Mulloy
Journal:  Blood       Date:  2006-05-02       Impact factor: 22.113

7.  Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.

Authors:  Leonard D Shultz; Bonnie L Lyons; Lisa M Burzenski; Bruce Gott; Xiaohua Chen; Stanley Chaleff; Malak Kotb; Stephen D Gillies; Marie King; Julie Mangada; Dale L Greiner; Rupert Handgretinger
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

8.  A robust xenotransplantation model for acute myeloid leukemia.

Authors:  P V Sanchez; R L Perry; J E Sarry; A E Perl; K Murphy; C R Swider; A Bagg; J K Choi; J A Biegel; G Danet-Desnoyers; M Carroll
Journal:  Leukemia       Date:  2009-07-23       Impact factor: 11.528

9.  Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.

Authors:  Junping Wei; Mark Wunderlich; Catherine Fox; Sara Alvarez; Juan C Cigudosa; Jamie S Wilhelm; Yi Zheng; Jose A Cancelas; Yi Gu; Michael Jansen; Jorge F Dimartino; James C Mulloy
Journal:  Cancer Cell       Date:  2008-06       Impact factor: 31.743

10.  NOD/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration.

Authors:  F E Nicolini; J D Cashman; D E Hogge; R K Humphries; C J Eaves
Journal:  Leukemia       Date:  2004-02       Impact factor: 11.528
  10 in total
  166 in total

1.  The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.

Authors:  Benjamin Mizukawa; Eric O'Brien; Daniel C Moreira; Mark Wunderlich; Cindy L Hochstetler; Xin Duan; Wei Liu; Emily Orr; H Leighton Grimes; James C Mulloy; Yi Zheng
Journal:  Blood       Date:  2017-08-04       Impact factor: 22.113

2.  PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Authors:  Paolo Neviani; Jason G Harb; Joshua J Oaks; Ramasamy Santhanam; Christopher J Walker; Justin J Ellis; Gregory Ferenchak; Adrienne M Dorrance; Carolyn A Paisie; Anna M Eiring; Yihui Ma; Hsiaoyin C Mao; Bin Zhang; Mark Wunderlich; Philippa C May; Chaode Sun; Sahar A Saddoughi; Jacek Bielawski; William Blum; Rebecca B Klisovic; Janelle A Solt; John C Byrd; Stefano Volinia; Jorge Cortes; Claudia S Huettner; Steffen Koschmieder; Tessa L Holyoake; Steven Devine; Michael A Caligiuri; Carlo M Croce; Ramiro Garzon; Besim Ogretmen; Ralph B Arlinghaus; Ching-Shih Chen; Robert Bittman; Peter Hokland; Denis-Claude Roy; Dragana Milojkovic; Jane Apperley; John M Goldman; Alistair Reid; James C Mulloy; Ravi Bhatia; Guido Marcucci; Danilo Perrotti
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

3.  The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment.

Authors:  Shan Lin; Roger T Luo; Mahesh Shrestha; Michael J Thirman; James C Mulloy
Journal:  Blood       Date:  2017-06-21       Impact factor: 22.113

4.  CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.

Authors:  S S Kenderian; M Ruella; O Shestova; M Klichinsky; V Aikawa; J J D Morrissette; J Scholler; D Song; D L Porter; M Carroll; C H June; S Gill
Journal:  Leukemia       Date:  2015-02-27       Impact factor: 11.528

5.  An MDS xenograft model utilizing a patient-derived cell line.

Authors:  G W Rhyasen; M Wunderlich; K Tohyama; G Garcia-Manero; J C Mulloy; D T Starczynowski
Journal:  Leukemia       Date:  2013-12-11       Impact factor: 11.528

6.  OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues.

Authors:  Mark Wunderlich; Ryan A Brooks; Rushi Panchal; Garrett W Rhyasen; Gwenn Danet-Desnoyers; James C Mulloy
Journal:  Blood       Date:  2014-04-28       Impact factor: 22.113

7.  Comparison of Human Hematopoietic Reconstitution in Different Strains of Immunodeficient Mice.

Authors:  Ashley I Beyer; Marcus O Muench
Journal:  Stem Cells Dev       Date:  2016-10-27       Impact factor: 3.272

8.  Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells.

Authors:  Benjamin H Durham; Damien Roos-Weil; Claude Baillou; Fleur Cohen-Aubart; Akihide Yoshimi; Makoto Miyara; Matthias Papo; Zofia Hélias-Rodzewicz; Nathalie Terrones; Neval Ozkaya; Ahmet Dogan; Raajit Rampal; Fanny Urbain; Lucie Le Fèvre; Eli L Diamond; Christopher Y Park; Thomas Papo; Frédéric Charlotte; Guy Gorochov; Valérie Taly; Olivier A Bernard; Zahir Amoura; Omar Abdel-Wahab; François M Lemoine; Julien Haroche; Jean-François Emile
Journal:  Blood       Date:  2017-05-31       Impact factor: 22.113

9.  Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.

Authors:  Guangyao Kong; Mark Wunderlich; David Yang; Erik A Ranheim; Ken H Young; Jinyong Wang; Yuan-I Chang; Juan Du; Yangang Liu; Sin Ruow Tey; Xinmin Zhang; Mark Juckett; Ryan Mattison; Alisa Damnernsawad; Jingfang Zhang; James C Mulloy; Jing Zhang
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

10.  A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment.

Authors:  Mark Wunderlich; Courtney Stockman; Mahima Devarajan; Navin Ravishankar; Christina Sexton; Ashish R Kumar; Benjamin Mizukawa; James C Mulloy
Journal:  JCI Insight       Date:  2016-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.